Cipla Australia Pty Ltd v Novo Nordisk A/S

Link copied
Case Copied 77 min read

FEDERAL COURT OF AUSTRALIA

Cipla Australia Pty Ltd v Novo Nordisk A/S [2024] FCA 1414  

File number: NSD 516 of 2024
Judgment of: PERRAM J
Date of judgment: 12 December 2024
Catchwords: PATENTS – patent for formulations of liraglutide – validity of extension of term of patent – where application for extension must concern a patent which discloses a ‘pharmaceutical substance per se’ under s 70 of the Patents Act 1990 – whether ‘pharmaceutical substance’ includes formulations of active ingredients and excipients – whether excipients required to be for distinct therapeutic use   
Legislation:

Acts Interpretation Act 1901 (Cth) s 11B

Intellectual Property Laws Amendment Act 1998 (Cth)

Intellectual Property Laws Amendment Act 2006 (Cth)

Intellectual Property Laws Amendment Act 2015 (Cth)

Patents (World Trade Organization Amendment) Act 1994 (Cth)

Patents Act 1903 (Cth) s 84

Patents Act 1952 (Cth) ss 6, 90, 94

Patents Act 1990 (Cth) ss 70, 71, 77, 78, 119A, 192, 223(2), 230, Sch 1

Patents Amendment Act 1989 (Cth)

Therapeutic Goods Act 1989 (Cth) s 3

Customs (Prohibited Imports) Regulations 1956 (Cth) reg 2

Patents Amendment Bill 1988 (Cth)

Patents Amendment Bill 1989 (Cth)

Cases cited:

Alphapharm Pty Ltd v H Lundbeck A/S [2008] FCA 559

Alphapharm Pty Ltd v H Lundbeck A/S [2014] HCA 42; 254 CLR 247

Baini v R [2012] HCA 59; 246 CLR 469

Boehringer Ingelheim International GmbH v Commissioner of Patents [2001] FCA 647; 112 FCR 595

Boehringer Ingelheim International v Commissioner for Patents [2000] FCA 1918

Commissioner of Patents v AbbVie Biotechnology Ltd [2017] FCAFC 129; 253 FCR 436

Commissioner of Stamps v Telegraph Investment Co Pty Ltd (1995) 184 CLR 453

H Lundbeck A/S v Alphapharm Pty Ltd [2009] FCAFC 70; 177 FCR 151

Hill v Zuda Pty Ltd [2022] HCA 21; 275 CLR 24

Novartis AG v Pharmacor Pty Ltd (No 3) [2024] FCA 1307

Pharmacia Italia SpA v Mayne Pharma Pty Ltd [2006] FCA 305; 69 IPR 1

Prejay Holdings Ltd v Commissioner of Patents [2003] FCAFC 77; 57 IPR 424

Project Blue Sky Inc v Australian Broadcasting Corporation [1998] HCA 28; 194 CLR 355

Spirit Pharmaceuticals Pty Ltd v Mundipharma Pty Ltd [2013] FCA 658; 216 FCR 344

Division: General Division
Registry: New South Wales
National Practice Area: Intellectual Property
Sub-area: Patents and associated Statutes
Number of paragraphs: 219
Date of last submissions: 11 November 2024
Date of hearing: 30 October-1 November 2024
Counsel for the Applicant/Cross-Respondent: Mr D Larish and Ms J McKenna
Solicitor for the Applicant/Cross-Respondent: Maddocks
Counsel for the Respondent/Cross-Claimant: Mr J Cooke SC and Ms M Evetts
Solicitor for the Respondent/Cross-Claimant: Corrs Chambers Westgarth

ORDERS

NSD 516 of 2024
BETWEEN:

CIPLA AUSTRALIA PTY LTD

Applicant

AND:

NOVO NORDISK A/S

Respondent

AND BETWEEN:

NOVO NORDISK A/S

Cross-Claimant

AND:

CIPLA AUSTRALIA PTY LTD

Cross-Respondent

ORDER MADE BY:

PERRAM J

DATE OF ORDER:

12 DECEMBER 2024

THE COURT ORDERS THAT:

1.The parties bring in short minutes of order to give effect to these reasons within…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Cipla Australia Pty Ltd v Novo Nordisk A/S and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2024] FCA 1414
Decision Date

CaseChat Overview and Summary

In the matter of Cipla Australia Pty Ltd v Novo Nordisk A/S, the Federal Court of Australia was tasked with determining the validity of a patent term extension application. The dispute centred on the interpretation of the term "pharmaceutical substance" under section 70 of the Patents Act 1990, specifically whether formulations of active ingredients and excipients qualify as a "pharmaceutical substance per se". The core legal issue was whether the excipients in the formulations of liraglutide claimed in the 862 Patent had to serve a distinct therapeutic use to be considered a "pharmaceutical substance".

The court examined the legislative history and current provisions of the Patents Act 1990 and found that the construction of "pharmaceutical substance" proposed by Cipla was contrary to its ordinary meaning and not supported by other provisions in the Act, legislative history, or case law. The court acknowledged a potential inconsistency with a High Court decision but ultimately decided that it was not bound by this obiter dictum, given it was not a considered statement. The court concluded that the formulations of liraglutide in question were not precluded from being "pharmaceutical substances" by virtue of being formulations. Additionally, the court rejected Cipla's alternative argument that the excipients in the formulations must have a distinct therapeutic use separate from the active ingredient, finding no such requirement under the Act.

The Federal Court of Australia ruled in favour of Novo Nordisk A/S, holding that the formulations of liraglutide in question were valid "pharmaceutical substances" under the Patents Act 1990. The court ordered the parties to submit minutes of order within seven days to give effect to the reasons provided.

Orders

Orders of the court

1. The parties bring in short minutes of order to give effect to these reasons within 7 days.

Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.

Background

Background to the litigation

Evidence

Evidence Before The Court

Decision

Reasons for decision

Viewing the course of authority as a whole, I am not persuaded that it would require me, or if not require then persuade me, to disregard my own conclusions following an exhaustive examination of the legislative history and the current provisions. Conclusions on Interpretation of ‘Pharmaceutical Substance’ I reject Cipla’s construction of ‘pharmaceutical substance’. It is contrary to its ordinary meaning, is not required by other provisions in the Act, is contrary to the legislative history and is not required by the case law. Further, the suggested legislative policy has not been shown sufficiently to exist. That said, I do accept that the reference to a tablet in footnote 40 in the High Court’s decision in Alphapharm, if not read as an illustration of a method, is inconsistent with the conclusion I have reached. My preferred reading of it is as a statement about method claims which would be consistent with the case law about what a pharmaceutical substance per se is. However, I acknowledge that I may be wrong about that and that if I am, then footnote 40 contradicts the conclusion I would otherwise reach. It is not at all clear where the High Court obtained the reference to a tablet but it seems to me that the most likely explanation is that it comes from the explanatory memorandum which accompanied the 2006 Act. However, as I have explained, the statement in that explanatory memorandum is legally incorrect. Although the High Court in Baini v R counselled against utilising paraphrases of legislation which appear not only in explanatory memoranda but also in judgments of courts, I do not apprehend the Court to have been suggesting the courts below it should depart from its paraphrasing of legislation. I do not therefore regard Baini v R as a licence to ignore footnote 40. I hesitate to depart from footnote 40, but it is not a considered obiter dictum and, as such, I am not legally required to follow it. Giving it the significant weight that it must nevertheless necessarily be accorded, I have come to the view that if it is not merely an illustration of a method claim, then I should respectfully not follow it. I do so hesitantly. THE ALTERNATIVE CASE It follows from the above that the two relevant formulations of liraglutide claimed in the 862 Patent are not precluded from being ‘pharmaceutical substances’ by virtue of their being formulations. It becomes necessary in light of this conclusion to consider Cipla’s alternative case that, even if ‘pharmaceutical substance’ is capable of encompassing formulations, it does not encompass either of the relevant formulations claimed by the 862 Patent. The pith of Cipla’s alternative case is that here, unlike in Spirit, the excipients do not individually or together have a therapeutic use in the formulations separate from the liraglutide itself. As already noted, there are two limbs to this point: first, somewhat obscurely, whether it is necessary that the excipients in a formulation themselves be for a therapeutic use in order that the formulation be a ‘pharmaceutical substance’; and secondly, if so, whether the excipients in the formulations claimed by the 862 Patent are for a therapeutic use.Limb 1: Must Excipients be for a Therapeutic Use?

Ratio Decidendi

Legal Principle Established